Healthcare News by GLG Council Members
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
-
Amyloid Beta does not correlate to Alzheimer Disease.
October 12, 2009
Bayer Schering ties-up with AC Immune for trial in Alzheimer´s disease | www.pharmabiz.com
The finding of amyloid-beta (Aβ) deposition in AD brains after death led to the so-called “amyloid hypothesis”. We have extensively reviewed the literature which claims that AD is caused by the deposition of Aβ within structures called senile plaques that invade AD brains and that such plaque formation then leads to further abnormalities within the nerve cells, eventually killing them.
-
Fampridine's FDA Pre-Meeting Report Raises Concerns About Efficacy and Safety
October 12, 2009
FDA Questions Efficacy of Acorda's MS Drug (Fampridine SR) | www.thestreet.com
The FDA released it's pre-meeting review online this past Friday, and clearly had some concerns. Acorda will need to address these very thoroughly and seriously.
-
Is the End of the Beginning of Diabetes Coming?
October 11, 2009
Andromeda Biotech Consummates Deal with Teva for the Commercialization of DiaPep277, its Late Stage Development Drug for Type 1 Diabetes | www.pipelinereview.com
Teva's global operations and recognition in association with many generic drugs of different classes and for different indications across many speciaties will be immensely helpful in marketing DiaPep277 worldwide.
-
Third to market but any advantages?
October 11, 2009
ONGLYZA™ (saxagliptin) Receives Marketing Authorisation In Europe For The Treatment Of Type 2 Diabetes | www.pipelinereview.com
With sitagliptin (Januvia, MRK) and vildagliptin (Galvus, NVS) already well established in the European market and the additional availability of the combination of these drugs with metformin, it seems unlikely that saxagliptin (Onglyza, BMS/AZ) will grab much of the market.
-
Expanding Treatment Options for Prostate Cancer
October 11, 2009
Medicare to cover controversial prostate treatment | www.philly.com
1. Medicare now covers Cyberknife radiosurgery treatment for prostate cancer in most parts of the United States.2. The Cyberknife has specific advantages over conventional surgery and conventional radiotherapy/IMRT for prostate cancer.3. Early clinical results on the use of Cyberknife radiosurgery for prostate cancer have been very favorable, with high rates of tumor control and minimal side effects.
-
Ken PowellPresidentGenesis Business Development, LLC
Swine Flu Could Benefit Reference Labs
October 10, 2009
Swine Flu Tests Could Swamp Diagnostic Labs | www.forbes.com
Leading experts have said that the H1N1 virus (swine flu) could benefit several segments and companies that compete in the clinical diagnostics market. However, there may be a very different way that the swine flu could impact certain labs and yield noticeable benefits to others.
-
Senate Finance Bill has the Greatest Potential to Reform Health Care Delivery
October 9, 2009
Health Care Bill Gets Green LIght in Cost Analysis | www.nytimes.com
The biggest boost that health care reform has received thus far occurred this week when the closely watched nonpartisan Congressional Budget Office (CBO) concluded that the Senate Finance Bill would actually reduce the federal deficit by $81 billion over the next 10 years and more beyond that. That set the stage for a vote on it by the full Committee next Tuesday, Oct. 13. It is expected to pass the Committee and then go to the Senate for floor debate by the week of Oct. 19.
-
FTY720 for Relapsing forms of MS
October 9, 2009
Two-year Phase III study shows Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression | www.pipelinereview.com
Fingolimod must be doing something right, because the latest study shows significant reduction in disability progression and relapse rates, even at the small doses tested (0.5 mg/d). Novartis is poised to submit an IND at the end of 2009 (very soon). The results of the FREEDOMS trial suggest that fingolimod is very effective in addressing the common indicators of therapeutic efficacy. Long-term studies will be required to further explore potential side effects and to document the extent of long-term benefit.
-
Ken PowellPresidentGenesis Business Development, LLC
Genetic Patent Recommendations Could Impact Diagnostic Companies
October 8, 2009
Task Force Advises Making Gene Patents Exempt from Infringement | www.genomeweb.com
The Secretary's Advisory Committee on Genetics, Health and Society (SACGHS) draft report on gene patents recommended that gene patents should be exempt from patent infringement. If this recommendation is implemented, it would have significant impact on many, if not all companies that offer high value, molecular diagnostic tests.
-
Ken PowellPresidentGenesis Business Development, LLC
October 8, 2009
Quidel, BioHelix to Co-Develop POC MDx Tests | www.genomeweb.com
Quidel and BioHelix have joined together to develop molecular point-of-care (POC) tests for infectious diseases. The synergies of this agreement provide Quidel with potentially high growth, POC infectious disease tests. BioHelix gains access to several market segments for its proprietary technology through Quidel.
- Subscribe to Updates
-
Leading institutions connect with members of the Healthcare councils through GLG
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 7 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Most Popular Healthcare News
-
What is potential future for Sequenom in prenatal testing.
November 9, 2009
-
November 7, 2009
-
Express Scripts feeling Growing Pains
October 29, 2009
-
CDC Outlines H1N1 Test Guidelines
October 8, 2009
-
Why Health Care Costs Keep Rising—And What to Do About It
September 13, 2009